When Depression Doesn’t Respond—Hope Still Exists with the Spravato Treatment NYC Citizens Need
If you’ve been living in New York City and struggling with Depression that just won’t lift, even after trying multiple medications and treatments, you are not alone. Emergent research shows that with Spravato NYC citizens may finally find meaningful relief.
A groundbreaking clinical trial recently published in JAMA Psychiatry in 2025 offers new hope to patients struggling to overcome their Depression. The study, conducted at 51 U.S. outpatient centers, found that esketamine nasal spray (branded as Spravato), when given as a standalone treatment, significantly and rapidly reduces depressive symptoms—even when other treatments have failed.
What Is Treatment-Resistant Depression (TRD)?
Many New Yorkers—despite access to top-tier psychiatric care—face treatment-resistant Depression (TRD), a form of Depression that doesn’t improve after two or more antidepressant trials.
TRD is diagnosed when a patient has major depressive disorder and has not experienced meaningful improvement after trying at least two different oral antidepressants at adequate doses and durations. For many, this lack of sufficient improvement can feel frustrating and exhausting—especially in a fast-paced, high-pressure environment like NYC.
Why TRD is Especially Challenging in New York City:
New York City is unlike any other urban environment in the country, making effective TRD treatments especially important given the following factors:
- The city’s intense work culture, long commutes, and high cost of living can exacerbate the impact of Depression
- Waiting months for a medication to “kick in” is not always realistic—especially when work, family, and personal life are negatively affected.
- Access to rapid-acting, effective treatments is especially important in areas with long winters and seasonally affective mood disorders.
The Esketamine Monotherapy Clinical Trial: What Was Studied
This Phase 4, double-blind, placebo-controlled randomized clinical trial was conducted from November 2020 to January 2024 across 51 outpatient centers in the U.S., including urban hubs similar in culture and capacity to that of NYC. Though ketamine and esketamine’s efficacy have been well documented when administered in conjunction with oral antidepressants, this trial investigated whether esketamine held the same promise as a monotherapy.
Key facts about the study:
- Participants: The study included 378 adults, average age 45, 61% female.
- Criteria: Each participant was clinically diagnosed with major depressive disorder per DSM-5, currently experiencing TRD.
- Treatment Protocol: Within the study, all participants stopped oral antidepressants for at least two weeks. They were randomly assigned to one of three groups:
- Esketamine nasal spray 56 mg
- Esketamine nasal spray 84 mg
- Placebo nasal spray
Dosing during treatment involved the usual protocol of administering esketamine twice weekly for 4 weeks.
Results of the Esketamine Monotherapy Clinical Trial: Fast, Significant Relief
The trial measured improvement in participants using the Montgomery–Åsberg Depression Rating Scale (MADRS), a standard clinical tool for assessing Depression severity.
By day 28 of the study, the results showed that for the 56 mg group, MADRS Depression scores dropped an average of 5.1 points more than that of their placebo counterpart. For the 84 mg group, MADRS Scores dropped even further, with an average of 6.8 points more than the placebo group.
The data offering insight into rapid response was also significant. Even just one day following their first dose, both esketamine groups had significantly better MADRS scores than placebo. For the 56 mg group, improvement measured approximately 3.8 points by day two, and for the 84 mg improvement was around 3.4 points at that time.
These results are incredibly meaningful for patients struggling with TRD; instead of waiting 6–8 weeks to feel an effect from traditional medication, some patients noticed meaningful improvement within 24 hours. With Spravato treatment NYC patients may discover the transformative potential of this new pathway that leads towards recovery.
Side Effects: What to Expect
Like all medications, esketamine has possible adverse side effects that patients should familiarize themselves with before considering this treatment. In the aforementioned study, the most common side effects included:
- Nausea (~25%)
- Dissociation (~24%)
- Dizziness (~22%)
- Headache (~19%)
The good news is that these effects are usually short-lived. At our Mid City TMS practice, patients receiving Spravato are observed for at least two hours during each session to ensure their absolute safety.
Why Esketamine Monotherapy Matters for New York City Patients
When it comes to approaching Spravato treatment NYC patients will want to consider the following benefits of esketamine:
- Rapid Onset of Action: NYC patients often can’t afford months of reduced productivity and enjoyment of activities—faster relief can be life-changing.
- Alternative to Oral Antidepressants: For those with side effects or limited success from conventional antidepressant pills, esketamine offers a new path toward relief.
- Supervised, In-Office Care: Sessions are given in our office under medical supervision, providing structure and support during treatment.
The Spravato Treatment Process in Our NYC Psychiatry Practice
Our Spravato NYC treatment process usually involves the following steps:
Step 1: Comprehensive Consultation
Together, we review your medical and psychiatric history, past treatments, and current symptoms.
Step 2: Treatment Planning
If you qualify for esketamine monotherapy, we fully develop and discuss a tailored plan—outlining your dose, schedule, and any integration with other supports and treatments.
Step 3: Administration in Our Office
You’ll self-administer the nasal spray under our supervision. We’ll then monitor you for two hours afterward.
Step 4: Tracking Progress
As you continue to administer Spravato, we use tools like the PHQ-9, BDI and MADRS to track changes, symptom improvement, and make appropriate adjustments to your treatment plan.
Step 5: Continuation or Maintenance
If symptoms improve, we plan for continued treatment or gradual reduction in the frequency of sessions, depending on your needs as they arise.
Frequently Asked Questions About Spravato NYC Treatment
- Is Spravato/esketamine nasal spray FDA-approved?
Yes! In 2019, the FDA authorized Spravato to be administered in combination with an oral antidepressant as TRD treatment modality. As of January 2025, the FDA has approved Spravato as a monotherapy (standalone treatment).
- Will my insurance cover it in NYC?
Most insurers cover esketamine for TRD. Our office assists in navigating and obtaining authorization for the medication and sessions with your insurance company, helping you to receive covered, affordable Spravato NYC treatment under your plan.
- Is it addictive?
When given in a controlled medical setting, the risk of developing an addiction to esketamine/Spravato is very low.
Why Choose Our Psychiatry Team for the Spravato Treatment NYC Needs
Mid City TMS has proudly assisted New Yorkers struggling with TRD for over three decades. Here’s what our psychiatry team has to offer:
- Longstanding expertise in TRD and cutting-edge treatments.
- Emphasis on collaboration with other providers.
- Centrally located in New York City for easy access.
- Evidence-based care, grounded in research like the 2025 JAMA Psychiatry trial.
- Warm, supportive environment with flexible scheduling, including evening hours until 8 PM, for busy New Yorkers who want to make time for treatment that works with their lifestyle.
Mid City TMS: Take the Next Step with Spravato Treatment NYC Can Rely On
If you’re living in New York and struggling with Depression that hasn’t improved with other treatments, esketamine could offer the next monumental step toward recovery with Spravato NYC treatment.
With over 30 years of experience treating complex Depression cases, Dr. Bryan Bruno and the compassionate team at Mid City TMS are ready to help you explore whether Spravato is right for you. Our Midtown Manhattan office offers extended hours to accommodate your schedule, and our staff will guide you through the insurance process to maximize your coverage.
Don’t wait another moment to start feeling better. The rapid relief that Spravato may provide could mean experiencing improvement in your symptoms within days—not weeks or months. Contact us today to schedule your initial consultation.
Sources
- Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Macaluso, M., Mattingly, G. W., Shelton, R. C., Zajecka, J. M., & Fu, D.-J. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2025.1317
- Anderer, S. Esketamine Monotherapy Effective for Treatment-Resistant Depression. JAMA. https://doi.org/10.1001/jama.2025.10978
- MDCalc. Montgomery-Åsberg Depression Rating Scale (MADRS). MDCalc. https://www.mdcalc.com/calc/4058/montgomery-asberg-depression-rating-scale-madrs